MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-12-2026
AVITA Medical Cost of Revenue 2011-2026 | RCEL
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue AVITA Medical
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 12.8 M | 9.09 M | 7.78 M | 6.04 M | 1.9 M | 2.97 M | 1.27 M | 546 K | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 12.8 M | 546 K | 5.3 M |
Quarterly Cost of Revenue AVITA Medical
| 2025-Q3 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.19 M | 2.83 M | - | 3.19 M | 2.11 M | 1.51 M | - | 2.11 M | 2.2 M | 1.67 M | - | 1.53 M | 1.39 M | 1.78 M | - | 1.09 M | 2.05 M | 2.15 M | 821 K | 929 K | 821 K | 929 K | 846 K | 619 K | 505 K | 292 K | 242 K | 232 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 3.19 M | 232 K | 1.46 M |
Cost of Revenue of other stocks in the Medical devices industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Acutus Medical
AFIB
|
10.3 M | - | -26.83 % | $ 2.62 M |  USA |
 |
Allied Healthcare Products
AHPI
|
24.5 M | - | 3.58 % | $ 2.21 M | USA |
 |
Alphatec Holdings
ATEC
|
232 M | $ 12.87 | -1.0 % | $ 1.93 B | USA |
 |
Aziyo Biologics
AZYO
|
13.7 M | - | 1.37 % | $ 20.5 M | USA |
 |
Bruker Corporation
BRKR
|
1.72 B | $ 38.31 | -0.51 % | $ 5.71 K | USA |
 |
Cognyte Software Ltd.
CGNT
|
104 M | $ 8.37 | 2.2 % | $ 601 M |  Israel |
 |
Conformis
CFMS
|
38.8 M | - | - | $ 16.4 M | USA |
 |
AdaptHealth Corp.
AHCO
|
2.64 B | $ 9.44 | -2.38 % | $ 1.28 B | USA |
 |
Apollo Endosurgery
APEN
|
34.4 M | - | - | $ 475 M | USA |
 |
Cardiovascular Systems
CSII
|
63.4 M | - | 0.15 % | $ 844 M | USA |
 |
CONMED Corporation
CNMD
|
624 M | $ 42.35 | -1.5 % | $ 1.31 B | USA |
 |
EDAP TMS S.A.
EDAP
|
37.6 M | $ 4.27 | 0.47 % | $ 159 M |  France |
 |
Cutera
CUTR
|
171 M | - | -10.19 % | $ 1.99 M | USA |
 |
Electromed
ELMD
|
14 M | $ 24.29 | - | $ 205 M | USA |
 |
Avinger
AVGR
|
5.65 M | - | -20.74 % | $ 369 K | USA |
 |
AxoGen
AXGN
|
57.9 M | $ 29.02 | -0.68 % | $ 1.34 B | USA |
 |
Apyx Medical Corporation
APYX
|
18.6 M | $ 3.23 | -2.12 % | $ 112 M | USA |
 |
Axonics Modulation Technologies
AXNX
|
76 M | - | - | $ 3.31 B | USA |
 |
Dynatronics Corporation
DYNT
|
21.4 M | - | 14.99 % | $ 929 K | USA |
 |
Eargo
EAR
|
23 M | - | - | $ 10.2 M | USA |
 |
Second Sight Medical Products
EYES
|
11.8 M | - | -0.97 % | $ 54.4 M | USA |
 |
Accuray Incorporated
ARAY
|
312 M | $ 0.52 | -0.9 % | $ 53.4 M | USA |
 |
Neovasc
NVCN
|
556 K | - | - | $ 111 M |  Canada |
 |
Cytosorbents Corporation
CTSO
|
10.5 M | $ 0.8 | 1.27 % | $ 43.5 M | USA |
 |
Align Technology
ALGN
|
1.2 B | $ 178.91 | -1.78 % | $ 13.4 B | USA |
 |
Butterfly Network
BFLY
|
33.2 M | $ 3.82 | -5.09 % | $ 809 M | USA |
 |
BIOLASE
BIOL
|
32.4 M | - | -13.19 % | $ 166 K | USA |
 |
Abbott Laboratories
ABT
|
19.3 B | $ 111.71 | -1.19 % | $ 194 B | USA |
 |
BioSig Technologies
BSGM
|
57 K | - | 37.08 % | $ 85.7 M | USA |
 |
InMode Ltd.
INMD
|
79.5 M | $ 13.57 | 0.04 % | $ 877 M | Israel |
 |
Boston Scientific Corporation
BSX
|
6.22 B | $ 71.83 | -0.53 % | $ 106 B | USA |
 |
IRadimed Corporation
IRMD
|
16.9 M | $ 103.22 | -1.8 % | $ 1.31 B | USA |
 |
IRIDEX Corporation
IRIX
|
30.1 M | $ 1.41 | - | $ 22.7 M | USA |
 |
OrthoPediatrics Corp.
KIDS
|
63.7 M | $ 17.71 | -4.15 % | $ 415 M | USA |
 |
Helius Medical Technologies
HSDT
|
583 K | $ 2.24 | -3.03 % | $ 1.36 M | USA |
 |
Pulmonx Corporation
LUNG
|
21.8 M | $ 1.64 | 13.89 % | $ 64.1 M | USA |
 |
Edwards Lifesciences Corporation
EW
|
1.33 B | $ 84.22 | -1.16 % | $ 49.3 B | USA |
 |
Medtronic PLC
MDT
|
11.6 B | $ 94.35 | -1.31 % | $ 121 B | USA |